"I am honored to be named a finalist for `CEO of the Year' at the European Lifestars Awards. This recognition reflects the remarkable progress Cereno Scientific has made over the past year, advancing two clinical HDAC inhibitor programs, strengthening our financial and strategic foundation, and building our visibility across the global life science community. It is also a testament to the trust of our shareholders, the dedication of our team, and the value of our partnerships. Together, we are demonstrating how an innovative biotech from Sweden can compete globally, shape new treatment paradigms, and deliver on our mission to bring pioneering treatments to patients suffering from rare cardiovascular and pulmonary diseases," said Sten R. Sörensen, CEO at Cereno Scientific.

The European Lifestars Awards is organized by LSX and EBD Group to honor the outstanding achievements of individuals, teams, and organizations driving innovation, advancing healthcare solutions, and shaping the future of the life sciences industry. The categories for the 2025 Awards include Seed Raise of the Year, Series A Raise of the Year, Series B Raise of the Year, Late Venture Round / Series C+ Raise of the Year, Post-IPO Raise of the Year, Venture Capital Firm of the Year, Pharma BD Team of the Year, Biotech of the Year, Medtech of the Year, Healthtech of the Year, Deal of the Year (<€500m), Deal of the Year (>€500m), M&A of the Year, Women-Led Business of the Year and CEO of the Year.

The European Lifestars Awards 2025 will take place on November 17, 2025, at the City Central @ Honourable Artillery Company in London, UK. For further information on the European Lifestars Awards, visit: informaconnect.com/european-lifestars-awards/.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and pulmonary hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.